These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38342136)

  • 1. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
    Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
    Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation.
    Bender JD; Oquendo-Del Toro H; Benoit J; Howell JC; Badia P; Davies SM; Grimley MS; Jodele S; Phillips C; Burns K; Marsh R; Nelson A; Wallace G; Dandoy CE; Pate A; Strine AC; Frias O; Breech L; Rose SR; Hoefgen H; Khandelwal P; Myers KC
    Transplant Cell Ther; 2023 Feb; 29(2):130.e1-130.e8. PubMed ID: 36323400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
    Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
    Transplant Cell Ther; 2023 Aug; 29(8):531.e1-531.e4. PubMed ID: 37169288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
    Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
    Oran B; Wagner JE; DeFor TE; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1327-34. PubMed ID: 21232621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease.
    George SA; Lai KW; Lewis RW; Bryson EW; Haight AE; Meacham LR
    Transplant Cell Ther; 2022 Nov; 28(11):770.e1-770.e6. PubMed ID: 35995392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding.
    Nakano H; Ashizawa M; Akahoshi Y; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
    Int J Hematol; 2016 Jul; 104(1):110-6. PubMed ID: 27084256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.
    Phelan R; Mann E; Napurski C; DeFor TE; Petryk A; Miller WP; Wagner JE; Verneris MR; Smith AR
    Bone Marrow Transplant; 2016 Oct; 51(10):1369-1375. PubMed ID: 27272448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant.
    Higgins A; Khan Z; Coddington CC; Hashmi SK; Hefazi M; Alkhateeb H; Litzow MR; Hogan WJ; Cathcart-Rake E; Thompson CA; Patnaik MM
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1232-1239. PubMed ID: 30772513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
    Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
    Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan.
    Panasiuk A; Nussey S; Veys P; Amrolia P; Rao K; Krawczuk-Rybak M; Leiper A
    Br J Haematol; 2015 Sep; 170(5):719-26. PubMed ID: 25974284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
    Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
    J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibin B and anti-Müllerian hormone as markers of gonadal function after hematopoietic cell transplantation during childhood.
    Laporte S; Couto-Silva AC; Trabado S; Lemaire P; Brailly-Tabard S; Espérou H; Michon J; Baruchel A; Fischer A; Trivin C; Brauner R
    BMC Pediatr; 2011 Feb; 11():20. PubMed ID: 21352536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.
    Chhabra S; Ahn KW; Hu ZH; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
    Blood Adv; 2018 Nov; 2(21):2922-2936. PubMed ID: 30396912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
    Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated Clinical Outcomes of Hematopoietic Stem Cell Transplantation Using Myeloablative Total Body Irradiation with Ovarian Shielding to Preserve Fertility.
    Ashizawa M; Akahoshi Y; Nakano H; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Wada H; Kawamura K; Sato M; Terasako-Saito K; Tanihara A; Kimura SI; Nakasone H; Kako S; Akahane K; Wakatsuki M; Shirai K; Kanda Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2461-2467. PubMed ID: 31394267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.